Saptak Chem and Business Ltd

Saptak Chem and Business Ltd reported a net loss of ₹0.30 crore for the fiscal year 2025-26. This marks a widening of the loss from ₹0.086 crore in the previous fiscal year. The company also registered gross sales of ₹0.0026 crore for FY26.

Reader Takeaway: Capital restructuring and a new ₹5 Cr order offer revival hopes amid continued losses and compliance gaps.

What just happened

Saptak Chem and Business Ltd has reported its financial results for the fiscal year 2025-26. The company posted a net loss of ₹0.30 crore (₹30.21 lakh), a significant increase from the ₹0.086 crore (₹8.62 lakh) loss in FY25. Gross sales for FY26 stood at ₹0.0026 crore (₹0.26 lakh), up from ₹0.0006 crore in the prior year. The company also announced securing a new purchase order worth approximately ₹5 crore, slated for execution in FY27.

Why this matters

The widening net loss indicates continued financial strain for Saptak Chem. However, the acquisition of a ₹5 crore order is a positive development that could potentially boost future revenues and operational activity. This, coupled with recent capital restructuring, suggests management's efforts to steer the company towards a revival.

The backstory

Saptak Chem is in an early stage of business revival. A scheme of capital reduction was implemented to write off accumulated losses, with BSE registering it on September 15, 2025. This involved a 90% reduction in share capital approved by the NCLT on June 23, 2025. The company operates in the Trading of Agricultural Produce segment. In November 2025, it allotted 4,000,000 convertible equity warrants to non-promoters at ₹10.50 each. Subsequently, in April 2026, 2,000,000 warrants were converted into equity shares.

What changes now

The capital reduction and preferential allotment have recalibrated the company's financial structure. The new ₹5 crore order provides a tangible business opportunity for FY27. Management is banking on these capital raises to reflect positively in future quarters. The issued, subscribed, and paid-up equity share capital stood at ₹1.07 crore as of March 31, 2026.

Risks to watch

The company faces risks related to continued financial losses, which widened in FY26. There are also documented instances of non-compliance with SEBI (LODR) Regulations, 2015, concerning the upload of Related Party Transactions in XBRL mode and newspaper publication of financial results and AGM notices. Furthermore, the successful execution of the ₹5 crore order is crucial and carries inherent risks.

Peer comparison

(No specific peer comparison data available in the filing.)

Context metrics (time-bound)

• Net Loss (FY26): ₹0.30 crore
• Gross Sales (FY26): ₹0.0026 crore
• New Order Win: Approx. ₹5 crore (for FY27 execution)
• Share Capital (as of Mar 31, 2026): ₹1.07 crore

What to track next

Investors should closely monitor the company's revenue generation and cost management in upcoming quarters. The successful execution and financial impact of the ₹5 crore order will be a key indicator. Additionally, compliance with SEBI regulations and any further board stability will be important factors to track.